Safety Board Says Phase 2 Temelimab Trial for MS Should Move Forward multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
4.6 (9)
People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey.
The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS), taking place virtually Feb. 25–27.
“For people living with a chronic disease such as MS, access to highly effective treatments and maintaining flexibility in their lives is paramount,” Estelle Vester-Blokland, MD, global head neuroscience medical affairs, Novartis Pharmaceuticals, said in a press release.
Low exposure to ultraviolet-B (UV-B) radiation from sunlight, which results in a defective synthesis of vitamin D, have been suggested to increase the risk for developing MS. However, it remains a matter of debate whether sunlight and vitamin D levels also influence disease severity and progression.
In this study, researchers in Germany assessed the impact of two independent measures of sunlight exposure vitamin D levels and latitude on MS disease severity. (Decreasing latitude is linked with an increase of sunlight that reaches the Earth’s surface.)
Also, they assessed whether the effects of sunlight exposure were modulated by medication or variations in the gene coding for the melanocortin 1 receptor (